SCHEMBL9519103

SCHEMBL9519103

O=C1c2ccccc2C(=O)N1Oc1ccccn1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.46
KMT2A Q03164 4/20 0.46
MEN1 O00255 2/20 0.46
PKM P14618 1/20 0.46
HSD17B10 Q99714 1/20 0.44
GAA P10253 2/20 0.42
MAPK1 P28482 1/20 0.41
KDM4E B2RXH2 4/20 0.40
MAPT P10636 3/20 0.40
CTSL P07711 1/20 0.40
PTPRC P08575 1/20 0.40
CTSS P25774 1/20 0.40
PTPN13 Q12923 1/20 0.40
HPGD P15428 1/20 0.40
HTT P42858 1/20 0.39
TSHR P16473 1/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
GRM5 P41594 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8616882 0.75 MEN1 (0.56) ALDH1A1KMT2AMEN1PKMHSD17B10
SCHEMBL7212283 0.71 RAB9A (0.62) ALDH1A1KMT2AMEN1PKMHSD17B10
SCHEMBL15647281 0.71 KMT2A (0.39) ALDH1A1KMT2AMEN1PKMGAA
SCHEMBL14577578 0.71 CHRM5 (0.59) ALDH1A1KMT2AMEN1PKMKDM4E
SCHEMBL8960362 0.70 RAB9A (0.56) ALDH1A1KMT2AMEN1PKMHSD17B10
SCHEMBL2219482 0.70 ALDH1A1 (0.58) ALDH1A1KMT2AMEN1PKMHSD17B10
SCHEMBL29280219 0.70
SCHEMBL31703779 0.70 ALDH1A1 (0.50) ALDH1A1KMT2AMEN1PKMGAA
SCHEMBL436166 0.70 ALDH1A1 (0.50) ALDH1A1KMT2AMEN1PKMGAA
SCHEMBL2098096 0.69 MAPT (0.40) ALDH1A1KMT2AMEN1GAAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200148679-A1 Novel compounds for the treatment, alleviation or prevention of disorders associated with Tau aggregates AC IMMUNE SA (CH) 2020-05-14 US disclosed
EP-0282077-B1 Pyridyloxy derivatives FUJIREBIO KK (JP) 1993-11-10 EP disclosed
US-4977267-A ANTISECRETORY AGENT FUJIREBIO KABUSHIKI KAISHA (JP) 1990-12-11 US disclosed
US-4912101-A Containing a secondary amide, suflur group and a furan ring FUJIREBIO KABUSHIKI KAISHA (JP) 1990-03-27 US disclosed
EP-0282077-A2 Pyridyloxy derivatives FUJIREBIO KABUSHIKI KAISHA (JP) 1988-09-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200148679-A1 Novel compounds for the treatment, alleviation or prevention of disorders associated with Tau aggregates MAPT, MAP1LC3A, MAP1LC3B ALDH1A1 3543/4885KMT2A 2583/4885MEN1 4482/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.